Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a mexican population.
Ann Endocrinol (Paris)
; 81(2-3): 78-82, 2020 Jun.
Article
em En
| MEDLINE
| ID: mdl-32340849
ABSTRACT
PURPOSE:
To describe pre- to post-treatment changes in clinical activity score (CAS) and exophthalmometry in patients with Graves orbitopathy treated with tocilizumab (TCZ). MATERIAL ANDMETHODS:
Eight Mexican patients presenting with active Graves orbitopathy (CAS>3/7) previously treated with glucocorticoids received 1 monthly dose of TCZ for 6 months. CAS, EUGOGO severity assessment and exophthalmometry were used to evaluate clinical status, with serum measurement of thyroid-stimulating hormone receptor antibodies (TR-Ab) for biochemical evaluation before and after application of TCZ.RESULTS:
Eight patients were analyzed 6 male (75%), 2 female (25%) mean age, 45.9±11.2 years; mean weight, 85±18.3 kg. Mean TR-Ab level at treatment outset was 291.9±96.4%, mean CAS 4.1±0.3 and mean exophthalmometry 21.2±3.2 mm. After TCZ treatment, mean TR-Ab level fell to 172.7±54% (P=0.001), mean CAS to 1.1±0.6 (P=0.001) and mean exophthalmometry to 19.3±2 mm (P=0.02).CONCLUSIONS:
TCZ is a therapeutic option for glucocorticoid-resistant orbitopathy, and should be considered in second line due to the cost of treatment or in first line in patients with contraindications to intravenous GC pulse therapy.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Resistência a Medicamentos
/
Oftalmopatia de Graves
/
Anticorpos Monoclonais Humanizados
/
Glucocorticoides
Tipo de estudo:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
País como assunto:
Mexico
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article